PMID- 32158297
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240328
IS  - 1179-2728 (Print)
IS  - 1179-2728 (Electronic)
IS  - 1179-2728 (Linking)
VI  - 11
DP  - 2020
TI  - Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy 
      of Crizotinib in Lung Adenocarcinoma Patients.
PG  - 19-25
LID - 10.2147/LCTT.S244366 [doi]
AB  - BACKGROUND: The ROS1 gene is a member of the "sevenless" subfamily of 
      tyrosine-kinase insulin-receptor genes. ROS1-fusion rearrangement causes 
      constitutive downstream signal transduction, with an oncogenic role in 
      non-small-cell lung carcinoma (NSCLC). Fortunately, crizotinib, an ALK1 
      tyrosine-kinase inhibitor, provides long-term disease control. The objective of 
      this molecular epidemiological study was to estimate the frequency of ROS1 
      rearrangements and evaluate treatment outcomes with crizotinib therapy. METHODS: 
      Patients with stage IV NSCLC adenocarcinoma histology were considered for this 
      study. The study was conducted according to the ethical principles stated in the 
      latest version of the Declaration of Helsinki and the applicable guidelines for 
      good clinical practice. Clinical characteristics and treatment details were 
      collected from patients' medical records. RESULTS: A total of 709 stage IV NSCLC 
      adenocarcinoma patients were included in the study. There were 457 (64.46%) men 
      and 252 (35.54%) women, with a median age of 60 years. ROS1-gene rearrangement 
      was positive in 20 (2.82%) cases, 13 using Fluorescent In-Situ Hybridization 
      (FISH), and two and five cases, respectively, using immunohistochemistry (IHC) 
      and next-generation sequencing (NGS), followed by confirmation with FISH. 
      Fourteen of the 20 patients with ROS1-gene rearrangement received crizotinib 
      therapy, with an objective response rate of 64.28%. At a median follow-up of 6 
      months, the study had not achieved the end points of median progression free 
      survival and overall survival. CONCLUSION: ROS1-gene rearrangement was present at 
      a relatively higher frequency of 2.8% in north Indian patients with 
      lung adenocarcinoma and was successfully targeted by crizotinib therapy. Although 
      the only US Food and Drug Administration and Conformite Europeenne approved 
      method for testing ROS1 rearrangement is NGS, FISH alone or IHC with D4D6 
      antibody as initial screen with subsequent confirmation of IHC-positive cases by 
      FISH are cost-effective methods in institutions lacking NGS facilities.
CI  - (c) 2020 Mehta et al.
FAU - Mehta, Anurag
AU  - Mehta A
AUID- ORCID: 0000-0001-6517-3664
AD  - Laboratory Services, Rajiv Gandhi Cancer Institute and Research Centre, New 
      Delhi, India.
FAU - Saifi, Mumtaz
AU  - Saifi M
AD  - Department of Molecular Pathology, Rajiv Gandhi Cancer Institute and Research 
      Centre, New Delhi, India.
FAU - Batra, Ullas
AU  - Batra U
AUID- ORCID: 0000-0003-3306-9824
AD  - Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, 
      India.
FAU - Suryavanshi, M
AU  - Suryavanshi M
AD  - Department of Molecular Pathology, Rajiv Gandhi Cancer Institute and Research 
      Centre, New Delhi, India.
FAU - Gupta, Kush
AU  - Gupta K
AD  - Catalyst Clinical Services, New Delhi, India.
LA  - eng
PT  - Journal Article
DEP - 20200224
PL  - New Zealand
TA  - Lung Cancer (Auckl)
JT  - Lung Cancer (Auckland, N.Z.)
JID - 101632521
PMC - PMC7047993
OTO - NOTNLM
OT  - NSCLC
OT  - ROS1
OT  - crizotinib
COIS- The authors report no conflicts of interest in this work. No benefits in any form 
      have been received or will be received from a commercial party related directly 
      or indirectly to the subject of this article.
EDAT- 2020/03/12 06:00
MHDA- 2020/03/12 06:01
PMCR- 2020/02/24
CRDT- 2020/03/12 06:00
PHST- 2019/12/31 00:00 [received]
PHST- 2020/02/11 00:00 [accepted]
PHST- 2020/03/12 06:00 [entrez]
PHST- 2020/03/12 06:00 [pubmed]
PHST- 2020/03/12 06:01 [medline]
PHST- 2020/02/24 00:00 [pmc-release]
AID - 244366 [pii]
AID - 10.2147/LCTT.S244366 [doi]
PST - epublish
SO  - Lung Cancer (Auckl). 2020 Feb 24;11:19-25. doi: 10.2147/LCTT.S244366. eCollection 
      2020.